Ksander Gary M, Shetty Suraj S, DelGrande Dominick, Balwierczak Joseph L, Bruseo Charles W, Savage Paula, deJesus Reynalda, Yuan Andrew, Webb Randy L, Jeng Arco Y
Metabolic and Cardiovascular Diseases Research, Novartis Institute for Biomedical Research, Summit, NJ 07901, USA.
Can J Physiol Pharmacol. 2002 May;80(5):464-9. doi: 10.1139/y02-028.
Endothelin-1 (ET-1) is a potent mitogen and modulator of vascular tone. It is synthesized and released from endothelial cells and acts upon two receptor subtypes designated as ETA and ETB. In this study, a series of potent dipeptide sulfonamide dual-endothelin ETA/ETB receptor antagonists were prepared to investigate their potential benefit in vascular diseases. CGS 31398 inhibited [125I]ET-1 binding to human ETA and ETB receptors expressed in Chinese hamster ovary (CHO) cells (ETA/CHO, ETB/CHO) with respective IC50 values of 0.26 and 0.12 nM. However, in anesthetized rats, this compound markedly potentiated ET-1-induced renal vascular resistance, a response normally observed with selective ETB receptor antagonists. To determine whether species differences account for these results, a direct comparison was made between binding to rat and rabbit aortic membranes versus functional antagonism in isolated rat aortic rings. It was found that CGS 31398 had potent affinity for the ETA receptor in rat and rabbit aorta with IC50 values of 0.87 and 0.79 nM, respectively. Inhibition of ET-1-induced contractions of rat aorta by the compound was considerably weaker than expected (pKB = 6.4), while that of sarafotoxin S6c induced contraction of dog saphenous vein (100% inhibition at 100 nM) was consistent with corresponding binding data. These results suggest that although CGS 31398 is a potent dual inhibitor of ETA/ETB receptor binding, it surprisingly displays potent ETB and weak ETA receptor antagonism in functional assays.
内皮素-1(ET-1)是一种强效的有丝分裂原和血管张力调节剂。它由内皮细胞合成并释放,作用于两种受体亚型,即ETA和ETB。在本研究中,制备了一系列强效的二肽磺酰胺双内皮素ETA/ETB受体拮抗剂,以研究它们在血管疾病中的潜在益处。CGS 31398抑制[125I]ET-1与中国仓鼠卵巢(CHO)细胞中表达的人ETA和ETB受体(ETA/CHO、ETB/CHO)的结合,其IC50值分别为0.26和0.12 nM。然而,在麻醉大鼠中,该化合物显著增强了ET-1诱导的肾血管阻力,这是选择性ETB受体拮抗剂通常观察到的反应。为了确定物种差异是否导致这些结果,对大鼠和兔主动脉膜结合与离体大鼠主动脉环中的功能拮抗作用进行了直接比较。发现CGS 31398对大鼠和兔主动脉中的ETA受体具有强效亲和力,IC50值分别为0.87和0.79 nM。该化合物对ET-1诱导的大鼠主动脉收缩的抑制作用明显弱于预期(pKB = 6.4),而对沙雷肽毒素S6c诱导的犬隐静脉收缩(100 nM时100%抑制)与相应的结合数据一致。这些结果表明,尽管CGS 31398是一种强效的ETA/ETB受体结合双重抑制剂,但令人惊讶的是,它在功能测定中表现出强效的ETB和弱的ETA受体拮抗作用。